Watts N B
Emory University School of Medicine, Atlanta, Georgia, USA.
Endocrinol Metab Clin North Am. 1998 Jun;27(2):419-39. doi: 10.1016/s0889-8529(05)70014-1.
Several bisphosphonates are effective for preventing bone loss associated with estrogen deficiency, glucocorticoid treatment, and immobilization, and for at least partially reversing bone loss in patients with postmenopausal osteoporosis and steroid-induced osteoporosis. The most promising of these agents are etidronate, alendronate, risedronate, and ibandronate. These drugs should have an important role in the prevention and treatment of osteoporosis; however, more research is needed regarding optimal doses and regimens (continuous versus intermittent, oral versus parenteral), comparisons with other agents, and their use in combination with other agents.
几种双膦酸盐对预防与雌激素缺乏、糖皮质激素治疗及制动相关的骨质流失有效，且至少能部分逆转绝经后骨质疏松症和类固醇诱导的骨质疏松症患者的骨质流失。其中最有前景的药物是依替膦酸二钠、阿仑膦酸钠、利塞膦酸钠和伊班膦酸钠。这些药物在骨质疏松症的预防和治疗中应发挥重要作用；然而，关于最佳剂量和给药方案（持续给药与间歇给药、口服给药与胃肠外给药）、与其他药物的比较以及它们与其他药物联合使用等方面，仍需要更多的研究。
